Novo Nordisk A/S (NVO) Traded Lower Due To Investor Disappointment Over Its New Drug In Obesity
Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” fourth quarter 2024 ...
Investing2d
Novo Nordisk A/S Class B (NOVOb)
(Reuters) - Novo Nordisk (NYSE:NVO) said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, ...
STAT9d
Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial
Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...
FiercePharma10d
Novo Nordisk invites people with Type 2 diabetes into their ‘Ozempic Eras’ in star-studded campaign
Novo Nordisk predicts milder growth in 2025 after obesity star Wegovy doubles sales in Q4 Becker’s contributions to the campaign, meanwhile, include Type 2 diabetes-friendly twists on recipes ...
Novo Nordisk Foundation’s obesity head works as paid adviser to chocolate maker Ferrero
Professor Arne Astrup is also involved in project to change widely-accepted definition of ultra-processed food ...
Novo Nordisk under pressure as obesity drug disappoints in diabetes trial
Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.
Yahoo Finance10d
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk ... obesity and type 2 diabetes”, said Martin Holst Lange, executive vice president for Development at Novo Nordisk.
Morgan Stanley says REDEFINE-2 misses opportunity to differentiate in diabetes
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...
Investing1d
Novo Nordisk A/S Class B (NOVOb)
ByInvesting.com • Oct 20, 2021 Cigna's pharmacy benefit unit to prefer cheaper insulin drug from Viatris (Reuters) - Cigna Corp (NYSE:CI)'s pharmacy benefit unit said on Wednesday it will prefer ...